Search

"To join Boehringer Ingelheim was the best ever decision"

Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.

Boehringer and ZEISS partnership eye diseases

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Boehringer Ingelheim becomes member of IPC

Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni

Accelerating new cancer medicines in partnership with CBmed

Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients

Joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Partnership WHO Foundation mental health

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Boehringer Ingelheim announces appointments

From social worker to joining the pharmaceutical industry

Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D

Collaboration with Mary Tyler Moore Vision Initiative

Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes

Boehringer Ingelheim acquires Global Stem cell Technology

Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health

Research-collaboration-Gubra-obesity-treatment

Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.

collaboration-kings-college-london

Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia

New partnership to develop schizophrenia treatments

Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments

Life forward - Boehringer Ingelheim company brand

Life forward - Boehringer Ingelheim unveils its evolved company brand

Boehringer Ingelheim announces appointments Board of Managing Directors

World Rabies Day: BI fights rabies misconceptions

Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.

Boehringer Ingelheim Second Transforming Science Day

World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day

Monoclonal antibodies Boehringer Ingelheim and Invetx

Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics

Cooperation with The Defeat-NCD Partnership